secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001830214-25-000013
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Q3 revenue $39M (-56% YoY); net loss $81M; reaffirms FY guide $167-187M
------------------------------------------------------------------------------

- Total revenue $39M, down 56% YoY; prior year had $45M non-cash deferred revenue; ex that, down 11%.
- GAAP net loss $81M vs $56M prior; Adjusted EBITDA loss $56M vs $20M.
- Reaffirms FY25 revenue $167-187M; Cell Engineering $117-137M; Biosecurity at least $40M.
- Cash & securities $462M; expands autonomous lab; Bayer partnership extended, BARDA contract up to $22.2M.
- Cell Engineering revenue $29M (-61% YoY); Biosecurity $9M ($14M prior).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000183021425000013/0001830214-25-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000183021425000013/dna-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001830214-25-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer